Skip to main content


Page 37 of 38

  1. Patients suffering from adult acute lymphoblastic leukemia are acutely ill and present most commonly with fever, pallor, bleeding, lymphadenopathy, hepatosplenomegaly and presence of lymphoblasts in the periph...

    Authors: Farhat Abbas Bhatti, Iftikhar Hussain and Muhammad Zafar Ali
    Citation: Journal of Hematology & Oncology 2009 2:26
  2. Non-prescriptional use of medicinal herbs among cancer patients is common around the world. The alleged anti-cancer effects of most herbal extracts are mainly based on studies derived from in vitro or in vivo ani...

    Authors: Godfrey Chi-Fung Chan, Wing Keung Chan and Daniel Man-Yuen Sze
    Citation: Journal of Hematology & Oncology 2009 2:25
  3. The ability to screen blood of early stage operable breast cancer patients for circulating tumour cells is of potential importance for identifying patients at risk of developing distant relapse. We present the...

    Authors: Michael P Raynor, Sally-Anne Stephenson, Kenneth B Pittman, David CA Walsh, Michael A Henderson and Alexander Dobrovic
    Citation: Journal of Hematology & Oncology 2009 2:24
  4. Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In approximately 60% of cases, ...

    Authors: Tara K Gregory, David Wald, Yichu Chen, Johanna M Vermaat, Yin Xiong and William Tse
    Citation: Journal of Hematology & Oncology 2009 2:23
  5. Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fift...

    Authors: Karen Seiter, Sreedhar Katragadda, Doris Ponce, Muhammad Rasul and Nasir Ahmed
    Citation: Journal of Hematology & Oncology 2009 2:21
  6. Ezatiostat hydrochloride liposomes for injection, a glutathione S-transferase P1-1 inhibitor, was evaluated in myelodysplastic syndrome (MDS). The objectives were to determine the safety, pharmacokinetics, and...

    Authors: Azra Raza, Naomi Galili, Natalie Callander, Leonel Ochoa, Lawrence Piro, Peter Emanuel, Stephanie Williams, Howard Burris III, Stefan Faderl, Zeev Estrov, Peter Curtin, Richard A Larson, James G Keck, Marsha Jones, Lisa Meng and Gail L Brown
    Citation: Journal of Hematology & Oncology 2009 2:20
  7. Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in as...

    Authors: Zhen-gang Yuan, Xiao-yi Dun, Yong-hua Li and Jian Hou
    Citation: Journal of Hematology & Oncology 2009 2:19
  8. Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten ras (KRAS) status has emerged as a predictor of response to epi...

    Authors: David Z Chang, Vikas Kumar, Ying Ma, Kuiyuan Li and Scott Kopetz
    Citation: Journal of Hematology & Oncology 2009 2:18
  9. We studied serum proteomic profiling in patients with graft versus host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT) by two-dimensional gel electrophoresis (2-DE) and mass spec...

    Authors: Joseph McGuirk, Gang Hao, Weijian Hou, Sunil Abhyankar, Casey Williams, Weisi Yan, Jianda Yuan, Xiuqin Guan, Robert Belt, Shaun Dejarnette, Jeffery Wieman and Ying Yan
    Citation: Journal of Hematology & Oncology 2009 2:17
  10. Malignant tumors that involve the skull base pose significant challenges to the clinician because of the proximity of critical neurovascular structures and limited effectiveness of surgical resection without m...

    Authors: Nicholas D Coppa, Daniel MS Raper, Ying Zhang, Brian T Collins, K William Harter, Gregory J Gagnon, Sean P Collins and Walter C Jean
    Citation: Journal of Hematology & Oncology 2009 2:16
  11. Human β-globin disorders are relatively common genetic diseases cause by mutations in the β-globin gene. Increasing the expression of the γ-globin gene has great benefits in reducing complications associated with...

    Authors: Xiaoxin S Xu, Xin Hong and Gan Wang
    Citation: Journal of Hematology & Oncology 2009 2:15
  12. R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) and R-CVP (rituximab with cyclophosphamide, vincristine and prednisone) have both been used successfully in the treatment of pa...

    Authors: Ganguly Siddhartha and Patel Vijay
    Citation: Journal of Hematology & Oncology 2009 2:14
  13. Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and ev...

    Authors: Bernardo HL Goulart, Jeffrey W Clark, Gregory Y Lauwers, David P Ryan, Nina Grenon, Alona Muzikansky and Andrew X Zhu
    Citation: Journal of Hematology & Oncology 2009 2:13
  14. Cholestatic jaundice as a presenting symptom of Precursor T-lymphoblastic leukemia (T-ALL)/lymphoma (T-LBL) has never been reported in literature. Similarly, precursor T-ALL/T-LBL is characteristically negativ...

    Authors: Kevin J Patel, Sahibzada U Latif and Wanderley M de Calaca
    Citation: Journal of Hematology & Oncology 2009 2:12
  15. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell lymphoma (ALCL). The latest...

    Authors: Brady Beltran, Jorge Castillo, Renzo Salas, Pilar Quiñones, Domingo Morales, Fernando Hurtado, Luis Riva and Eric Winer
    Citation: Journal of Hematology & Oncology 2009 2:11
  16. We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have disc...

    Authors: Milind Javle and Chung-Tsen Hsueh
    Citation: Journal of Hematology & Oncology 2009 2:9
  17. The Bcl-2 family of proteins is critical to the life and death of malignant B-lymphocytes. Interfering with their activity using small-molecule inhibitors (SMI) is being explored as a new therapeutic strategy ...

    Authors: Ayad M Al-Katib, Yuan Sun, Anton Scott Goustin, Asfar Sohail Azmi, Ben Chen, Amro Aboukameel and Ramzi M Mohammad
    Citation: Journal of Hematology & Oncology 2009 2:8
  18. Recent research has supported that a variety of cytokines play important roles during radiation-induced lung toxicity. The present study is designed to investigate the differences in early cytokine induction a...

    Authors: Xiaoping Ao, Lujun Zhao, Mary A Davis, David M Lubman, Theodore S Lawrence and Feng-Ming Kong
    Citation: Journal of Hematology & Oncology 2009 2:6
  19. We highlight the orbital manifestations of acute myeloid leukemia and the role of peripheral blood smear in the diagnosis of these cases. A total of 12 patients who presented with proptosis and were subsequent...

    Authors: Ramesh Murthy, Geeta K Vemuganti, Santosh G Honavar, Milind Naik and Vijayanand Reddy
    Citation: Journal of Hematology & Oncology 2009 2:4
  20. SET-NUP214 fusion resulting from a recurrent cryptic deletion, del(9)(q34.11q34.13) has recently been described in T-cell acute lymphoblastic leukemia (T-ALL) and in one case of acute myeloid leukemia (AML). The ...

    Authors: Hilmar Quentmeier, Björn Schneider, Sonja Röhrs, Julia Romani, Margarete Zaborski, Roderick AF MacLeod and Hans G Drexler
    Citation: Journal of Hematology & Oncology 2009 2:3
  21. Curative surgery is not an option for many patients with clinical stage I non-small-cell lung carcinoma (NSCLC), but radical radiosurgery may be effective.

    Authors: Brian T Collins, Saloomeh Vahdat, Kelly Erickson, Sean P Collins, Simeng Suy, Xia Yu, Ying Zhang, Deepa Subramaniam, Cristina A Reichner, Ismet Sarikaya, Giuseppe Esposito, Shadi Yousefi, Carlos Jamis-Dow, Filip Banovac and Eric D Anderson
    Citation: Journal of Hematology & Oncology 2009 2:1
  22. Concurrent hemolysis in patients with vitamin B12 deficiency is a well-recognized phenomenon and has been attributed to intramedullary destruction of erythrocytes (ineffective erythropoiesis). Recent studies r...

    Authors: Utkarsh Acharya, Jen-Tzer Gau, William Horvath, Paolo Ventura, Chung-Tsen Hsueh and Wayne Carlsen
    Citation: Journal of Hematology & Oncology 2008 1:26
  23. Prostate cancer remains the most common malignancy among elderly men and the second leading cause of cancer death in the United States. Although several conventional therapies are currently available, they hav...

    Authors: Paul Pyo, Brandon Louie, Srinivas Rajamahanty, Muhammad Choudhury and Sensuke Konno
    Citation: Journal of Hematology & Oncology 2008 1:25
  24. The etiology of venous thromboembolism in young patients is frequently associated with hereditary coagulation abnormalities, immunologic diseases, and neoplasia. The advent of radiological advances, namely Com...

    Authors: Cannon Milani, Maria Constantinou, David Berz, James N Butera and Gerald A Colvin
    Citation: Journal of Hematology & Oncology 2008 1:24
  25. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome (TTP-HUS) are related and uncommon disorders with a high fatality and complication rate if untreated. Plasma exchange therapy has been show...

    Authors: Mark Levandovsky, Danielle Harvey, Primo Lara and Ted Wun
    Citation: Journal of Hematology & Oncology 2008 1:23
  26. Antiandrogen withdrawal response is an increasingly recognized entity in patients with metastatic prostate cancer. To our knowledge, there have been no reports describing a durable radiologic improvement along wi...

    Authors: Yiu-Keung Lau, Manpreet K Chadha, Alan Litwin and Donald L Trump
    Citation: Journal of Hematology & Oncology 2008 1:21
  27. This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, G...

    Authors: Andrea Molckovsky and Lillian L Siu
    Citation: Journal of Hematology & Oncology 2008 1:20
  28. Excessive maturation of hematopoietic cells leads to a reduction of long-term proliferative capability during cord blood (CB) expansion. In this study, we report the effects of anit-CD52 (Alemtuzumab, Campath)...

    Authors: Che K Lim, Li Sun, Qi Feng, Ping Law, Wei T Chua, Shy N Lim and William YK Hwang
    Citation: Journal of Hematology & Oncology 2008 1:19
  29. Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer...

    Authors: Brian J So, Tanios Bekaii-Saab, Mark A Bloomston and Tushar Patel
    Citation: Journal of Hematology & Oncology 2008 1:18
  30. We have analyzed t(12;21)(p13:q22) in an attempt to evaluate the frequency and prognostic significance of TEL-AML1 fusion gene in patients with childhood CD 10 positive B-ALL by fluorescence in situ hybridization...

    Authors: Eman Mosad, Hosny B Hamed, Rania M Bakry, Azza M Ezz-Eldin and Nesrine M Khalifa
    Citation: Journal of Hematology & Oncology 2008 1:17
  31. Breast cancer is the most common female cancer and the second most common cause of female cancer-related deaths in the United States. World-wide, more than one million women will be diagnosed with breast cance...

    Authors: David Chu and Janice Lu
    Citation: Journal of Hematology & Oncology 2008 1:16
  32. L-arginine is the common substrate for the two isoforms of arginase. Arginase I, highly expressed in the liver and arginase II mainly expressed in the kidney. Arginase I-producing myeloid derived suppressor ce...

    Authors: David J Tate Jr, Derek J Vonderhaar, Yupanqui A Caldas, Toye Metoyer, John R Patterson IV, Diego H Aviles and Arnold H Zea
    Citation: Journal of Hematology & Oncology 2008 1:14
  33. The most common semiquantitative method of evaluation of pulmonary lesions using 18F-FDG PET is FDG standardized uptake value (SUV). An SUV cutoff of 2.5 or greater has been used to differentiate between benign a...

    Authors: Majid Khalaf, Hani Abdel-Nabi, John Baker, Yiping Shao, Dominick Lamonica and Jayakumari Gona
    Citation: Journal of Hematology & Oncology 2008 1:13
  34. Amplification of the ERBB2 (Her-2/neu) oncogene, which occurs in approximately 25% of breast carcinomas, is a known negative prognostic factor. Available data indicate that a variable number of nearby genes on ch...

    Authors: Lydia Usha, Bita Tabesh, Larry E Morrison, Ruta D Rao, Kris Jacobson, April Zhu, Sanjib Basu and John S Coon
    Citation: Journal of Hematology & Oncology 2008 1:12
  35. In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical on...

    Authors: David Chu and Shenhong Wu
    Citation: Journal of Hematology & Oncology 2008 1:11
  36. Molecular characterisation of normal karyotype acute myeloid leukemia (NK-AML) allows prognostic stratification and potentially can alter treatment choices and pathways. Approximately 45–60% of patients with N...

    Authors: Angela YC Tan, David A Westerman, Dennis A Carney, John F Seymour, Surender Juneja and Alexander Dobrovic
    Citation: Journal of Hematology & Oncology 2008 1:10
  37. Previous studies demonstrated Ganoderma lucidum polysaccharides (GL-PS), a form of bioactive β-glucan can stimulate the maturation of monocyte-derived dendritic cells (DC). The question of how leukemic cells espe...

    Authors: Wing Keung Chan, Christopher Ching Hang Cheung, Helen Ka Wai Law, Yu Lung Lau and Godfrey Chi Fung Chan
    Citation: Journal of Hematology & Oncology 2008 1:9

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2022 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    74 days submission to accept (Median)

    2022 Usage 
    9,883 Altmetric mentions 

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here